Satavaptan | 185913-78-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: Satavaptan
• 英文别名: N-tert-butyl-4-[5'-ethoxy-4-(2-morpholin-4-ylethoxy)-2'-oxospiro[cyclohexane-1,3'-indole]-1'-yl]sulfonyl-3-methoxybenzamide
• CAS: 185913-78-4
• 化学式: C₃₃H₄₅N₃O₈S
• 分子量: 643.8
• InChiKey: QKXJWFOKVQWEDZ-UHFFFAOYSA-N

物化性质

• 密度：
  1.31±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  45
• 可旋转键数：
  11
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.58
• 拓扑面积：
  132
• 氢给体数：
  1
• 氢受体数：
  9

文献信息

• Auris Formulations for Treating Otic Diseases and Conditions
  申请人：Otonomy, Inc.

  公开号：US20160243028A1

  公开（公告）日：2016-08-25

  Disclosed herein are compositions and methods for the treatment of otic disorders with immunomodulating agents and auris pressure modulators. In these methods, the auris compositions and formulations are administered locally to an individual afflicted with an otic disorder, through direct application of the immunomodulating and/or auris pressure modulating compositions and formulations onto the auris media and/or auris interna target areas, or via perfusion into the auris media and/or auris interna structures.

  本文公开了使用免疫调节剂和耳压调节剂治疗耳部疾病的组合物和方法。在这些方法中，通过将免疫调节和/或耳压调节组合物和配方直接应用于耳媒介和/或耳内靶区，或通过向耳媒介和/或耳内结构灌注，局部给予患有耳部疾病的个体耳部组合物和配方。
• Controlled release aural pressure modulator compositions and methods for the treatment of OTIC disorders
  申请人：Otonomy, Inc.

  公开号：US10232044B2

  公开（公告）日：2019-03-19

  Disclosed herein are compositions and methods for the treatment of otic diseases or conditions with aural pressure modulating agent compositions and formulations administered locally to an individual afflicted with an otic disease or condition, through direct application of these compositions and formulations onto or via perfusion into the targeted auris structure(s).

  本文公开了耳压调节剂组合物和制剂治疗耳部疾病或病症的组合物和方法，通过将这些组合物和制剂直接涂抹在目标耳廓结构上或通过灌注到目标耳廓结构中，对耳部疾病或病症患者进行局部给药。
• Auris formulations for treating otic diseases and conditions
  申请人：Otonomy, Inc.

  公开号：US10751281B2

  公开（公告）日：2020-08-25

  Disclosed herein are compositions and methods for the treatment of otic disorders with immunomodulating agents and auris pressure modulators. In these methods, the auris compositions and formulations are administered locally to an individual afflicted with an otic disorder, through direct application of the immunomodulating and/or auris pressure modulating compositions and formulations onto the auris media and/or auris interna target areas, or via perfusion into the auris media and/or auris interna structures.

  本文公开了使用免疫调节剂和耳压调节剂治疗耳部疾病的组合物和方法。在这些方法中，通过将免疫调节剂和/或免疫调节压力调节剂组合物和制剂直接施用到耳道介质和/或耳道间质目标区域，或通过灌注到耳道介质和/或耳道间质结构中，对耳道疾病患者进行局部给药。
• Triglyceride otic formulations and uses thereof
  申请人：Otonomy, Inc.

  公开号：US10821185B2

  公开（公告）日：2020-11-03

  Disclosed herein are triglyceride based formulations, compositions, and methods for the treatment of otic diseases and conditions. Such triglyceride based formulations and compositions are derived from medium chain triglycerides and allow for the delivery of a variety of therapeutic agents to the outer, middle, and/or inner ear.

  本文公开了用于治疗耳部疾病和病症的甘油三酯制剂、组合物和方法。 此类甘油三酯制剂和组合物源自中链甘油三酯，可向外耳、中耳和/或内耳输送多种治疗剂。
• Auris formulations for treating OTIC diseases and conditions
  申请人：Otonomy, Inc.

  公开号：US11123285B2

  公开（公告）日：2021-09-21

  Disclosed herein are compositions and methods for the treatment of otic disorders with immunomodulating agents and auris pressure modulators. In these methods, the auris compositions and formulations are administered locally to an individual afflicted with an otic disorder, through direct application of the immunomodulating and/or auris pressure modulating compositions and formulations onto the auris media and/or auris interna target areas, or via perfusion into the auris media and/or auris interna structures.

  本文公开了使用免疫调节剂和耳压调节剂治疗耳部疾病的组合物和方法。在这些方法中，通过将免疫调节剂和/或免疫调节压力调节剂组合物和制剂直接施用到耳道介质和/或耳道间质目标区域，或通过灌注到耳道介质和/或耳道间质结构中，对耳道疾病患者进行局部给药。